Buscar
Congreso SOLACI

Búsqueda de: everolimus-eluting bioresorbable scaffolds,

Si no está conforme con los resultados, inténtelo de nuevamente.
Coronary disease

Very Late Thrombosis: Bioresorbable Scaffolds vs. Everolimus-Eluting Metallic Drug-Eluting Stents

This study sought to compare the 2-year outcomes between bioresorbable vascular scaffolds (BVS) and everolimus-eluting metallic drug-eluting...
solaci -
Ir
Coronary disease

1-Year Clinical Outcomes of Everolimus-Eluting Bioresorbable Vascular Scaffolds in Diabetic Patients

Original title: 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds A Pooled Analysis of...
solaci -
Ir
Chronic Ischemic cardiopathy

EuroPCR 2021 | FUTURE II: Bioresorbable Scaffolds Reloaded

A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to...
solaci -
Ir
Coronary disease

TCT 2018 | ABSORB IV: Much Life Left for Bioresorbable Scaffolds

Previous studies have documented higher rates of adverse events with bioresorbable scaffolds (ABSORB) compared with metallic drug-eluting...
solaci -
Ir
Chronic Ischemic cardiopathy

More Bad News on Bioresorbable Scaffolds

A year after the implantation of everolimus-eluting bioresorbable scaffold Absorb 1.1, optical coherence tomography (OCT) scans showed neointima...
solaci -
Ir
Coronary disease

Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique

 Courtesy of the SBHCI. The Absorb IV trial randomized 2604 patients in a 1:1 ratio to receive an Absorb everolimus-eluting...
solaci -
Ir
Coronary disease

ABSORB II: No Benefits from Scaffolds After Complete Bioresorption

 Courtesy of the SBHCI. The ABSORB II study sought to assess the mechanical properties of everolimus-eluting bioresorbable scaffolds, such...
solaci -
Ir
Coronary disease

Very Late Thrombosis in Bioresorbable Scaffolds

The presence of a metallic device interrupts normal laminar flow and creates an artery environment that favors...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad